Article
Evaluating new treatments for anaplastic thyroid cancer.
Expert review of anticancer therapy - 1 Nov 2022
Coca-Pelaz Andrés, Rodrigo Juan P, Lopez Fernando, Shah Jatin P, Silver Carl E, Al Ghuzlan Abir, Menke-van der Houven van Oordt C Willemien, Smallridge Robert C, Shaha Ashok R, Angelos Peter, Mendenhall William M, Piazza Cesare, Olsen Kerry D, Corry June, Tufano Ralph P, Sanabria Alvaro, Nuyts Sandra, Nathan Cherie-Ann, Vander Poorten Vincent, Dias Fernando Luiz, Suarez Carlos, Saba Nabil F, de Graaf Pim, Williams Michelle D, Rinaldo Alessandra, Ferlito Alfio
Abstract excerpt
INTRODUCTION: Anaplastic thyroid cancer (ATC) is one of the most lethal diseases known to humans with a median survival of 5 months. The American Thyroid Association (ATA) recently published guidelines for the treatment of this dreadful thyroid malignancy. AREAS COVERED: This review presents the current therapeutic landscape of this challenging disease. We also present the results from trials published over the...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.